Trial Profile
A Randomized Controlled Double-Blind Trial of Fentanyl Nasal Spray (Lazanda) Plus Hydromorphone Demand PCA Versus Placebo Nasal Spray Plus Hydromorphone Demand PCA for Treatment of Breakthrough Cancer Pain in the Emergency Department
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 16 Oct 2020
Price :
$35
*
At a glance
- Drugs Fentanyl (Primary) ; Hydromorphone
- Indications Cancer pain
- Focus Therapeutic Use
- 18 Jan 2017 Status changed from suspended to discontinued.
- 09 Feb 2015 Planned primary completion date changed from 1 Jan 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov.
- 09 Feb 2015 Status changed from discontinued to suspended as reported by ClinicalTrials.gov.